Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

NCT06413992 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

117

Enrollment

OTHER

Sponsor class

Conditions

Endometrial Carcinoma
TP53 Mutation
Recurrent or Metastatic

Interventions

DRUG: Fluzoparib
DRUG: Camrelizumab
DRUG: paclitaxel (albumin bound)
DRUG: Carboplatin injection
DRUG: Carboplatin
RADIATION: External irradiation

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences